ReviewEuropean journal of radiology open2023
Gadolinium contrast agents- challenges and opportunities of a multidisciplinary approach: Literature review.
Review in European journal of radiology open, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 64 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
64 citing papers in PubMed, 2 syntheses or guidelines pooled it, 154 citations in OpenAlex.
- Do Gadolinium-Based Contrasts Represent a High Risk for Genotoxicity in Mammalian Cells? A Systematic Review.Journal of applied toxicology : JAT · 2025Pooled it
- Evolving Characteristics of Gadolinium-Based Contrast Agents for MR Imaging: A Systematic Review of the Importance of Relaxivity.Journal of magnetic resonance imaging : JMRI · 2025Pooled it
- Article
- Manganese-Doped Carbon Nanodots as Next-Generation MRI and Fluorescence Imaging Agents.ACS nano · 2026Article
- In-Depth optimization and characterization of prostatic and penile vessel imaging with Ferumoxytol-enhanced magnetic resonance imaging.Medical physics · 2026Article
- Characterizing chronic obstructive pulmonary disease using quantitative MRI biomarkers.The British journal of radiology · 2026Review
- A Global Imprint of Gadolinium-Based Contrast Agents Used in Magnetic Resonance Imaging in Drinking Water.Environmental science & technology · 2026Article
- Peptide-Based pH-Responsive MRI-CEST Agents: In Vivo Comparison between a Selected Pentapeptide and the Established Iopamidol Reference in Tumor pH Mapping Ability.Chemical & biomedical imaging · 2026Article
- Single Molecule EuJournal of the American Chemical Society · 2026Article
- 3D Cell Printing and Manipulation with Magnetic Bioinks.Biomedicines · 2026Review
- In Vivo Tracking Modalities for Oncolytic Reovirus: Principles, Clinical Applications, and Translational Integration.Molecular imaging and biology · 2026Review
- MRI-guided diagnosis and dual-pathway neuroprotection in ischemic strokeMaterials today. Bio · 2026Article
- Gadolinium-Based Contrast Agents and the Theater of Safety.Clinical journal of the American Society of Nephrology : CJASN · 2026Article
- Intraindividual evaluation of gadopiclenol and gadobenate dimeglumine in liver MRI: impact on enhancement efficiency.Abdominal radiology (New York) · 2026Article
- Gadolinium-Doped Iron Oxide Nanoparticles Enhance Radiosensitivity in Melanoma Models Associated with Metabolic Dysfunction.Pharmaceutics · 2026Article
- Contrast-Enhanced MR Fingerprinting With Delta-Relaxometry: Investigating a New Avenue for Tumor Characterization.Journal of magnetic resonance imaging : JMRI · 2026Observational
- Synthesis of BSA-Coated Iron Oxide Nanoparticles with Size Control for High-PerformanceBiomolecules · 2026Article
- Investigating Cu(II) Complexes for MRI: A Comprehensive Approach Using EPR, Relaxometry, and Computational Modeling.Inorganic chemistry · 2026Article
- Cerebral Accumulation of Gadolinium (GdTomography (Ann Arbor, Mich.) · 2026Article
- Gadolinium Pollution-A Future Forward Perspective on Human and Environmental Impact.Magnetic resonance in medicine · 2026Review
4 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Contrast agents is used in magnetic resonance imaging (MRI) to improve the visibility of the details of the organ structures. Gadolinium-based contrast agent (GBCA) has been used since 1988 in MRI for diagnostic and follow-up of patients, the gadolinium good properties make it an effective choice for enhance the signal in MRI by increase its intensity and shortening the relaxation time of the proton. Recently, many studies show a gadolinium deposition in different human organs due to release of free gadolinium various body organs or tissue, which led to increased concern about the use of gadolinium agents, in this study, the potential diseases that may affect the patient and side effects that appear on the patient and related to accumulation of gadolinium were clarified, the study focused on the organs such as brain and bones in which gadolinium deposition was found and the lesions associated with it, and the diseases associated with gadolinium retention includes Nephrogenic Systemic Fibrosis (NSF) and Gadolinium deposition disease (GDD). Some studies tended to improve the contrast agents by developing a new non-gadolinium agents or development of next-generation gadolinium agents. In this review article the latest knowledge about MRI contrast agent.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.